<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822883</url>
  </required_header>
  <id_info>
    <org_study_id>C07-03-01</org_study_id>
    <nct_id>NCT04822883</nct_id>
  </id_info>
  <brief_title>Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia</brief_title>
  <official_title>A Single-arm, Single-blind, Multiple Dose Study to Evaluate Safety and the Effects of RL-007 on Electroencephalograms and Event-related Potentials in Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recognify Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recognify Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effects on electrical activity in the&#xD;
      brain of an investigational drug (RL-007) for improving cognition in patients with&#xD;
      schizophrenia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants will first be given an Informed Consent document and have the study&#xD;
      explained to them. All patients who provide written informed consent will undergo screening&#xD;
      to determine eligibility for the study. Patients who meet all eligibility criteria will be&#xD;
      admitted to the clinic for 5 days / 4 nights as an in-patient. During this time, participants&#xD;
      will be assigned to a specific dose cohort and will receive sequence that includes both&#xD;
      placebo and RL-007. Brain activity and cognitive performance will be assessed on study days 2&#xD;
      and 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Four dose cohorts will be enrolled sequentially.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will not be informed of their dose cohort or of the sequence of placebo or active capsules.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>Study Day 8.</time_frame>
    <description>Comparison of AE rates between active and placebo dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure (systolic and diastolic) from baseline</measure>
    <time_frame>Study Day 4</time_frame>
    <description>blood pressure measured in mmHg; baseline = Day -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate from baseline</measure>
    <time_frame>Study Day 4</time_frame>
    <description>heart rate measured in beats per minute; baseline = Day -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory rate from baseline</measure>
    <time_frame>Study Day 4</time_frame>
    <description>respiratory rate measured in breaths per minute; baseline = Day -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in temperature from baseline</measure>
    <time_frame>Study Day 4</time_frame>
    <description>temperature measured in degrees Celsius; baseline = Day -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in electrocardiogram (ECG) from baseline</measure>
    <time_frame>Study Day 3</time_frame>
    <description>overall physician interpretation of ECG reading; baseline = Day -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Columbia Suicide Severity Rating Scale (C-SSRS) from baseline</measure>
    <time_frame>Study Day 8</time_frame>
    <description>The C-SSRS assesses suicidal ideation and behavior; baseline = Day -1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quantitative electroencephalogram (qEEG)</measure>
    <time_frame>Study Day 4</time_frame>
    <description>change from baseline in amplitude across qEEG frequency bands (alpha, beta, delta, theta, and gamma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in evoked response potential (ERP) amplitude</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Change from baseline in signal amplitude of the two-stimulus auditory oddball ERP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in evoked response potential (ERP) latency</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Change from baseline in signal latency of the two-stimulus auditory oddball ERP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in amplitude of mismatch negativity (MMN) ERP</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Change from baseline in signal amplitude of the MMN ERP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in latency of mismatch negativity (MMN) ERP</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Change from baseline in signal latency of the MMN ERP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Verbal learning performance</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Number of words recalled (immediate and delayed) on the Hopkins Verbal Learning Test (HVLT-R)</description>
  </other_outcome>
  <other_outcome>
    <measure>Symbol coding performance</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Number of correct responses on the Brief Assessment of Cognition in Schizophrenia Symbol Coding Test</description>
  </other_outcome>
  <other_outcome>
    <measure>Category fluency performance</measure>
    <time_frame>Study Day 4</time_frame>
    <description>Number of appropriate items provided in the Category Fluency Task</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Dose-escalation - RL-007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort will include a single dose-strength. Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-escalation - matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Within each cohort, the sequence of active capsules and matching placebo capsules will be varied and unknown to the participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RL-007</intervention_name>
    <description>Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing</description>
    <arm_group_label>Dose-escalation - RL-007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RL-007 Matching Placebo</intervention_name>
    <description>Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing</description>
    <arm_group_label>Dose-escalation - matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Provide a written informed consent&#xD;
&#xD;
          -  Diagnosis of schizophrenia, as defined by DSM-5 and evaluated with the MINI Plus&#xD;
             interview&#xD;
&#xD;
          -  Positive and Negative Symptoms Severity Score (PANSS) of 40 - 80 (inclusive), and a&#xD;
             score of 4 or less on the following PANSS items: P2, P3, P5, P6, G6.&#xD;
&#xD;
          -  Currently being treated with a single protocol-allowed antipsychotic at a stable dose&#xD;
             and clinically stable for at least 8 weeks before admission (note: allowed meds =&#xD;
             aripiprazole, brexipiprazole, paliperidone, risperidone)&#xD;
&#xD;
          -  Modified Simpson-Angus Scale total score &lt;= 4&#xD;
&#xD;
          -  At least 1 standard deviation below normative value of total number of words recalled&#xD;
             on the Hopkins Verbal Learning Test&#xD;
&#xD;
          -  BMI &lt;= 38&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of hospitalization for medical indication within 4 weeks prior to screening or&#xD;
             psychiatric hospitalization within 3 months prior to screening&#xD;
&#xD;
          -  Use of any other psychoactive medication known to interfere with the EEG/ERP&#xD;
             assessments within 1 week prior to screening or during the study period.&#xD;
&#xD;
          -  Subjects who present a serious risk of suicide&#xD;
&#xD;
          -  Any history of GI surgery, or other condition, that may affect GI absorption or any&#xD;
             history of GI bleeding or peptic ulcer.&#xD;
&#xD;
          -  Evidence or history of significant cognitive impairment, other than associated with&#xD;
             schizophrenia, that in the judgement of the Investigator would confound secondary or&#xD;
             exploratory assessments or prevent safe and satisfactory completion of the study&#xD;
             protocol.&#xD;
&#xD;
          -  Moderate to severe alcohol use disorder, per DSM-5 within 3 months of admission visit.&#xD;
&#xD;
          -  Positive alcohol breath test or urine test for drugs of abuse at either screening or&#xD;
             admission visit.&#xD;
&#xD;
          -  Currently smoking more than 1 pack of cigarettes a day and unable or unwilling to&#xD;
             maintain smoking to less than 1 pack a day during in-patient portion of study.&#xD;
&#xD;
          -  Positive test result for SARS-CoV2 prior to admission per site standards.&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C or HIV&#xD;
&#xD;
          -  Subjects whose hair type or style is likely to interfere with successful application&#xD;
             of scalp electrodes.&#xD;
&#xD;
          -  Subjects with needle phobia or in whom venous access is technically difficult.&#xD;
&#xD;
          -  Other unspecified reasons that, in the opinion of the PI or sponsor, make the subject&#xD;
             unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Walling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Neuroscience Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>510-552-0136</phone>
    <email>gary.walker@recognify.life</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CEO</last_name>
      <phone>714-799-7799</phone>
    </contact>
    <investigator>
      <last_name>David Walling, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

